Yamanouchi Pharmaceutical Co., Ltd.

Data show solifenacin succinate reduced urgency episodes for overactive bladder

Published in Health Insurance Week, August 29th, 2004

Solifenacin succinate, a once-daily oral antimuscarinic agent in development for the treatment of overactive bladder (OAB), significantly reduced urgency episodes in a pooled analysis of four pivotal trials involving more than 2800 patients, according to data presented at the annual meeting of the American Urogynecologic Society (AUGS).

OAB is a condition that affects approximately 17 million men and women in the United States.

According to the definition of OAB by the International Continence Society, the defining symptom of OAB is urgency, or the sudden, compelling desire to urinate that is difficult to defer. From this data, solifenacin appears to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Insurance Week

Source: Health Insurance Week (2004-08-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry